Intracerebral Hemorrhage
Conditions
Keywords
Intracerebral haemorrhage, Functional recovery, Chinese herbal medicine, Stroke, Clinical trial
Brief summary
TCM is an essential context of the ICH management in Chinese culture. Given the potential benefits of Chinese herbal medicine FYTF-919 in reducing haematoma and bleeding after acute ICH from fundamental research and small clinical studies, more reliable evidence is required to guide ICH treatment using TCM. This study aims to determine the effectiveness and safety of TCM in a larger sample of patients with moderate-severe ICH and provide evidence for TCM clinical guidelines on ICH management. The presumed mechanism of action is in promoting the reabsorption of the haematoma and perihematomal oedema in ICH.
Detailed description
A multicentre, prospective, randomised, double-blind, placebo-controlled trial to be conducted through hospital network of investigators in China. A total of 1504 patients with ICH will be recruited from approximately 20-30 hospitals. Randomised is via a central internet-based system according to block random grouping method stratified by site, neurological severity NIHSS \<15 vs ≥15), and haematoma location (basal ganglia + lobe vs thalamus + cerebellum + brain stem + ventricle) to ensure balance in key prognostic factors. Endpoint assessment will be blinded to treatment allocation. The primary aim of this study is to determine the effectiveness and safety of a Chinese herbal medicine FYTF-919 as compared to placebo on functional recovery according to Utility-weighted modified Rankin scale (UW-mRS) at 90 days after acute ICH. Secondary aims include examining whether the Chinese herbal medicine FYTF-919 leads to positive treatment effect on: 1) Utility-weighted mRS scores at 180 days; 2)Ordinal analysis of 7 levels of mRS at 28 days, 90 days and 180 days; 3) Poor prognosis, defined as mRS 4-6 points at 28 days, 90 days and 180 days; 4) NIHSS score at 7 days and 28 days; 5) Mortality rate at 28 days, 90 days and 180 days; 6) Discharge rate at 28 days; 7) EQ-5D-5L at 28days, 90 days and 180 days; 8) BI at 28 days, 90 days and 180 days; 9) The cerebral edema volume at baseline, 24 hours, 7 days, 14 days or at discharge; 10) The hematoma volume at baseline, 24 hours, 7 days, 14 days or discharge; 11) The incidence of stroke-associated pneumonia (SAP) patients; 12) Clinical pulmonary infection score (CIPS) at the onset of SAP, 3 days, and 7 days, after the occurrence of SAP; 13) Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture at the onset of SAP, 3 days, and 7 days after the occurrence of SAP; 14) Antibiotic usage among patients with SAP.
Interventions
Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
Sponsors
The George Institute
Guangzhou University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years; 2. Diagnosis of spontaneous ICH, confirmed by brain imaging; 3. Presentation within 48 hours of symptom onset (or last seen well); 4. Meet any of the following criteria: a) NIHSS ≥8, or b) GCS 7-14; 5. Provide written informed consent by patient (or approved surrogate);
Exclusion criteria
1. ICH secondary to a structural abnormality in the brain (e.g. cerebrovascular malformation, arterial aneurysm, tumour, Moyamoya disease, trauma, or previous ischaemic stroke), or secondary to presumed cerebrovascular amyloidosis, or secondary to reperfusion treatment for ischaemic stroke, or secondary to anticoagulant treatment, or secondary to antiplatelet treatment. 2. Unlikely to potentially benefit from therapy (e.g. advanced dementia) or judged by responsible treating clinician to have a high likelihood of early death irrespective of treatment; 3. Other medical illness that will interfere with outcome assessments and follow-up (e.g. known significant pre-stroke disability \[modified Rankin scale {mRS} scores 4-5\], advanced cancer and renal failure); 4. Known definite contraindication to the Chinese herbal medicine; 5. Women who are known to be pregnant or lactating; 6. Currently participating in another trial which would interfere with outcome assessments.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Utility-weighted modified Rankin scale scores | 90 days after the treatment started | Utility-weighted modified Rankin scale scores. The value range from 0 to 10: higher scores mean a better outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 7 levels of mRS | 28 days, 90 days and 180 days after the treatment started | Ordinal analysis of 7 levels of mRS. The value range 0-6: higher scores mean a worse outcome. |
| Poor prognosis rate | 28 days, 90 days and 180 days after the treatment started | Binary variable: 1 means mRS 4-6 points; 0 means mRS is 0-3 points. |
| NIHSS score | 7 days and 28 days after the treatment started | National Institute of Health Stroke Scale Score. The value range 0-42: higher scores mean a worse outcome. |
| Mortality rate | 28 days, 90 days and 180 days | Mortality rate |
| Discharge rate | 28 days after the treatment started | Discharge rate |
| European Quality of Life 5-dimensional questionnaire (EQ-5D-5L) | 28 days, 90 days and 180 days after the treatment started | The EQ-5D comprises five dimensions of health: mobility, ability to self-care, ability to undertake usual activities, pain and discomfort, and anxiety and depression. . EQ-5D-5L, includes five levels of severity for each dimension (no problems, slight problems, moderate problems, severe problems, and extreme problems). The value range 0-100: higher scores mean a worse outcome. |
| Utility-weighted mRS scores | 180 days after the treatment started | Utility-weighted modified Rankin scale scores. The value range from 0 to 10: higher scores mean a better outcome. |
| The cerebral edema volume | Baseline, 24 hours, 7 days, 14 days or at discharge | The cerebral edema volume |
| The hematoma volume | Baseline, 24 hours, 7 days, 14 days or discharge | The hematoma volume |
| SAP | Baseline, 24 hours, 7 days, 14 days or discharge | The incidence of stroke-associated pneumonia patients |
| CPIS | The onset of SAP, 3 days and 7 days after the occurrence of SAP | Clinical pulmonary infection score. The value range 0-12: higher scores mean a worse outcome. |
| Pulmonary infection | The onset of SAP, 3 days and 7 days after the occurrence of SAP | Diagnosed by using the Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture |
| Antibiotic usage | The onset of SAP, 3 days and 7 days after the occurrence of SAP | Antibiotic usage among patients with SAP |
| BI | 28 days, 90 days and 180 days after the treatment started | Barthel index. The value range 0-100: higher scores mean a better outcome. |
Countries
China
Contacts
Primary ContactJianwen Guo, MD
Outcome results
None listed